KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2021 - 2025)

Historic Liabilities from Discontinued Operations for TherapeuticsMD (TXMD) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • TherapeuticsMD's Liabilities from Discontinued Operations fell 878.93% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 878.93%. This contributed to the annual value of $2.8 million for FY2024, which is 2471.58% down from last year.
  • Latest data reveals that TherapeuticsMD reported Liabilities from Discontinued Operations of $2.7 million as of Q3 2025, which was down 878.93% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Liabilities from Discontinued Operations registered a high of $47.9 million during Q4 2021, and its lowest value of $1.4 million during Q2 2023.
  • Its 5-year average for Liabilities from Discontinued Operations is $8.8 million, with a median of $2.9 million in 2024.
  • As far as peak fluctuations go, TherapeuticsMD's Liabilities from Discontinued Operations plummeted by 8569.94% in 2023, and later surged by 33760.93% in 2024.
  • Over the past 5 years, TherapeuticsMD's Liabilities from Discontinued Operations (Quarter) stood at $47.9 million in 2021, then plummeted by 46.09% to $25.8 million in 2022, then plummeted by 85.7% to $3.7 million in 2023, then dropped by 24.72% to $2.8 million in 2024, then decreased by 4.1% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.8 million during Q1 2025.